Supporting Business Development for a Unique Protein Drug Optimization Technology

Founded by scientists who pioneered the fields of biosynthetic incorporation of novel amino acids and recombinant protein-based drugs, Ambrx had the science wrapped up. The company wanted to utilize PR to get its story out to prospective investors and large pharmaceutical and biotech companies that could partner with Ambrx to leverage the new technology to its fullest extent.

Ambrx contacted Russo Partners just before the company took the podium at the JPMorgan Healthcare Conference, one of the most important investor conferences of the year. The agency helped to fine-tune the Ambrx story and the materials used to tell it. After a polishing and honing of the message – and a successful media relations program that relayed important clinical trial data – Ambrx enjoyed its new high profile and leveraged it into significant partnerships with major pharmaceutical companies, including Eli Lilly and EMD Serono, in a single year.

Return to Case Studies